Mehmet Deniz ALTIPARMAK, Celal İsmail BİLGİÇ, Nüzhet Cenap DENER, Esra GÜNDÜZ, Sibel YENİDÜNYA, Muradiye ACAR, Meral ŞEN, Mehmet GÜNDÜZ

The effect of survivin gene promoter polymorphism on breast cancer

Breast cancer is the most common malignant tumor in women and accounts for about 25% of all cancer diagnoses. Survivin is a member of the apoptosis inhibitor protein family of antiapoptotic proteins. In our study, we investigated one of those, the survivin gene promoter 31G/C polymorphism. Included in this study were 111 breast cancer patients who were operated on in our hospital and 101 healthy female subjects. Blood samples from the healthy subjects and paraffin-embedded tissue samples from the patients were used for DNA extraction and subsequent genetic analysis. PCR-RFLP was used for genotype analysis. We established the clinicopathologic characteristics of patients. No significant difference was found between survivin 31G/C promoter polymorphism of tumor characteristics and breast cancer. Between the control and breast cancer groups, survivin promoter polymorphism 31G/C differences were not significantly different (P = 0.058). The risk of developing cancer, having the relevant GC or CC genotype, is 1.413 times higher than those having genotype GG (95% confidence interval: 1.040 to 1.918). Carrying the C allele was statistically significant in terms of susceptibility to breast cancer. In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is recommended based on the results of this study.

Anahtar Kelimeler:

Breast cancer, apoptosis inhibitor protein, survivin, survivin gene promoter polymorphism, SNP

The effect of survivin gene promoter polymorphism on breast cancer

Keywords:

Breast cancer, apoptosis inhibitor protein, survivin, survivin gene promoter polymorphism, SNP,

PDF

___

Altieri DC (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7: 542–547.
Altieri DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46–54.
Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917–921.
Ambrosini G, Adida C, Sirugo G, Altieri DC (1998). Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177–11182.
Bayram S, Akkız H, Bekar A, Akgöllü E (2011). The association between the survivin –31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 35: 555–559.
Borbély AA, Murvai M, Szarka K, Kónya J, Gergely L, Hernádi Z, Veress G (2007). Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60: 303–306.
Borges Bdo N, Burbano RR, Harada ML (2011). Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 11: 189–193.
Christensen LA, Finch RA, Booker AJ, Vasquez KM (2006). Targeting oncogenes to improve breast cancer chemotherapy. Cancer Rese 66: 4089–4094.
Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N (2009). Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24: 145–150.
Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al. (2008). Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60: 31–39.
Liu Y, Du F, Chen W, Yao M, Lv K, Fu P (2014). EIF5A2 is a novel chemoresistance gene in breast cancer. Breast Cancer. Mar 18.
Qin C, Cao Q, Li P, Ju X, Wang M, Chen J, Wu Y, Meng X, Zhu J, Zhang Z et al. (2012). Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 7: e28829.
Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F (2003). Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55: 1341–1347.
Srivastava K, Srivastava A, Mittal B (2012). Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 39: 1509–1516.
Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M (2010). Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 39: 976–980.
Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349–4354.
Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B (2011). Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 18: 880–887.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K et al. (2009). American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235–3258.
Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, Shen CH (2009). Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 73: 670–674.
Xu Y, Fang F, Ludewig G, Jones G, Jones D (2004). A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23: 527–537.
Yamamoto T, Tanigawa N (2001). The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34: 207–212.
Yamamoto T, Manome Y, Miyamoto A, Tanigawa N (2003). Development of a novel gene therapy using survivin antisense expressing adenoviral vectors. Gan To Kagaku Ryoho 30: 1805–1808.
Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K (2007). Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27: 2803–2808.
Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, Dong H, Sun Q, Cong R, Chen G et al. (2009). The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 54: 1021–1028.
Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi MT, Larijani B, Mostaan LV et al. (2012). Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 15; 208: 100–103.
Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, Mahrampour E, Larijani B, Tavakkoly-Bazzaz J, Amoli MM (2012). Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 22: 35–37.